Publication | Closed Access

Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans

VaccinationVaccine SafetyVaccine DevelopmentDose EscalationVaccine TargetImmunologyRoute Comparison StudyVaccine TestingMedicineVaccine ResearchPhase 1